Summary of findings 3. Dopamine agonist versus other active intervention.
| Dopamine agonist vs other active intervention | |||||||
|
Patient or population: women of reproductive age undergoing any ART therapy Settings: ART unit Intervention: dopamine agonist Comparison: other active intervention | |||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | Comments | ||
| Risk with other active intervention | Risk with dopamine agonist | ||||||
| Incidence of moderate or severe OHSS | Cabergoline vs human albumin | 432 per 1000 | 138 per 1000 (84 to 225) |
OR 0.21 (0.12 to 0.38) |
296 (3 RCTs) | ⊕⊝⊝⊝ Verylowa,b,c | — |
| Cabergoline vs prednisolone | 93 per 1000 | 27 per 1000 (5 to 120) |
OR 0.27 (0.05 to 1.33) |
150 (1 RCT) | ⊕⊝⊝⊝ Verylowa,b,d | — | |
| Cabergoline vs hydroxyethyl starch | 67 per 1000 | 161 per 1000 (33 to 519) |
OR 2.69 (0.48 to 15.10) |
61 (1 RCT) | ⊕⊝⊝⊝ Verylowa,b,d | — | |
| Cabergoline vs coasting | 125 per 1000 | 57 per 1000 (25 to 119) |
OR 0.42 (0.18 to 0.95) |
320 (3 RCTs) | ⊕⊝⊝⊝ Verylowa,b,c | — | |
| Cabergoline vs calcium infusion | 60 per 1000 | 105 per 1000 (53 to 196) |
OR 1.83 (0.88 to 3.81) |
400 (2 RCTs) | ⊕⊝⊝⊝ Very lowa,b,c | — | |
| Cabergoline vs diosmin | 120 per 1000 | 280 per 1000 (155 to 450) |
OR 2.85 (1.35 to 6.00) |
200 (1 RCT) | ⊕⊝⊝⊝ Verylowa,b,d | — | |
| Live birth rate | Cabergoline vs coasting or calcium infusion | 395 per 1000 | 414 per 1000 (323 to 510) |
OR 1.08 (0.73 to 1.59) |
430 (2 RCTs) | ⊕⊕⊝⊝ Lowa,b | — |
| Clinical pregnancy rate | Cabergoline vs human albumin, coasting, calcium infusion, or diosmin | 432 per 1000 | 442 per 1000 (381 to 503) |
OR 1.04 (0.81 to 1.33) |
1060 (7 RCTs) | ⊕⊕⊕⊝ Moderatea | — |
| Multiple pregnancy rate | Cabergoline vs human albumin, coasting, or diosmin | 130 per 1000 | 115 per 1000 (66 to 192) |
OR 0.87 (0.47 to 1.59) |
400 (3 RCTs) | ⊕⊕⊝⊝ Lowa,b | — |
| Miscarriage rate | Cabergoline vs human albumin, coasting, calcium infusion, or diosmin | 79 per 1000 | 54 per 1000 (29 to 97) |
OR 0.66 (0.35 to 1.25) |
630 (4 RCTs) | ⊕⊕⊝⊝ Lowa,b | — |
| Any other adverse events | Cabergoline vs calcium infusion | 0 per 1000 | 0 per 1000 (0 to 0) |
Not estimable | 170 (1 RCT) |
Not estimable | — |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ART: assisted reproductive technology; CI: confidence interval; OHSS: ovarian hyperstimulation syndrome; OR: odds ratio; RCT: randomised controlled trial. | |||||||
| GRADE Working Group grades of evidence High quality: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | |||||||
aDowngraded one level for risk of bias associated with poor reporting of study methods. bDowngraded one level for serious imprecision; total number of events fewer than 400. cDowngraded one level for serious inconsistency; I² greater than 50. dDowngraded one level for serious indirectness; single small study.